Cargando…

The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with no known cure, characterized by the formation of scar tissue in the lungs, leading to respiratory failure. Although the exact cause of IPF remains unclear, the condition is thought to result from a combination of gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Vats, Amrita, Chaturvedi, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505024/
https://www.ncbi.nlm.nih.gov/pubmed/37719787
http://dx.doi.org/10.2147/SCCAA.S419474
_version_ 1785106831058665472
author Vats, Amrita
Chaturvedi, Pankaj
author_facet Vats, Amrita
Chaturvedi, Pankaj
author_sort Vats, Amrita
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with no known cure, characterized by the formation of scar tissue in the lungs, leading to respiratory failure. Although the exact cause of IPF remains unclear, the condition is thought to result from a combination of genetic and environmental factors. One of the most widely used animal models to study IPF is the bleomycin-induced lung injury model in mice. In this model, the administration of the chemotherapeutic agent bleomycin causes pulmonary inflammation and fibrosis, which closely mimics the pathological features of human IPF. Numerous recent investigations have explored the functions of various categories of stem cells in the healing process of lung injury induced by bleomycin in mice, documenting the beneficial effects and challenges of this approach. Differentiation of stem cells into various cell types and their ability to modulate tissue microenvironment is an emerging aspect of the regenerative therapies. This review article aims to provide a comprehensive overview of the role of stem cells in repairing bleomycin-induced lung injury. It delves into the mechanisms through which various types of stem cells, including mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, and lung resident stem cells, exert their therapeutic effects in this specific model. We have also discussed the unique set of intermediate markers and signaling factors that can influence the proliferation and differentiation of alveolar epithelial cells both during lung repair and homeostasis. Finally, we highlight the challenges and opportunities associated with translating stem cell therapy to the clinic for IPF patients. The novelty and implications of this review extend beyond the understanding of the potential of stem cells in treating IPF to the broader field of regenerative medicine. We believe that the review paves the way for further advancements in stem cell therapies, offering hope for patients suffering from this debilitating and currently incurable disease.
format Online
Article
Text
id pubmed-10505024
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-105050242023-09-17 The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis Vats, Amrita Chaturvedi, Pankaj Stem Cells Cloning Review Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease with no known cure, characterized by the formation of scar tissue in the lungs, leading to respiratory failure. Although the exact cause of IPF remains unclear, the condition is thought to result from a combination of genetic and environmental factors. One of the most widely used animal models to study IPF is the bleomycin-induced lung injury model in mice. In this model, the administration of the chemotherapeutic agent bleomycin causes pulmonary inflammation and fibrosis, which closely mimics the pathological features of human IPF. Numerous recent investigations have explored the functions of various categories of stem cells in the healing process of lung injury induced by bleomycin in mice, documenting the beneficial effects and challenges of this approach. Differentiation of stem cells into various cell types and their ability to modulate tissue microenvironment is an emerging aspect of the regenerative therapies. This review article aims to provide a comprehensive overview of the role of stem cells in repairing bleomycin-induced lung injury. It delves into the mechanisms through which various types of stem cells, including mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, and lung resident stem cells, exert their therapeutic effects in this specific model. We have also discussed the unique set of intermediate markers and signaling factors that can influence the proliferation and differentiation of alveolar epithelial cells both during lung repair and homeostasis. Finally, we highlight the challenges and opportunities associated with translating stem cell therapy to the clinic for IPF patients. The novelty and implications of this review extend beyond the understanding of the potential of stem cells in treating IPF to the broader field of regenerative medicine. We believe that the review paves the way for further advancements in stem cell therapies, offering hope for patients suffering from this debilitating and currently incurable disease. Dove 2023-09-12 /pmc/articles/PMC10505024/ /pubmed/37719787 http://dx.doi.org/10.2147/SCCAA.S419474 Text en © 2023 Vats and Chaturvedi. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Vats, Amrita
Chaturvedi, Pankaj
The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
title The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
title_full The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
title_fullStr The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
title_full_unstemmed The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
title_short The Regenerative Power of Stem Cells: Treating Bleomycin-Induced Lung Fibrosis
title_sort regenerative power of stem cells: treating bleomycin-induced lung fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505024/
https://www.ncbi.nlm.nih.gov/pubmed/37719787
http://dx.doi.org/10.2147/SCCAA.S419474
work_keys_str_mv AT vatsamrita theregenerativepowerofstemcellstreatingbleomycininducedlungfibrosis
AT chaturvedipankaj theregenerativepowerofstemcellstreatingbleomycininducedlungfibrosis
AT vatsamrita regenerativepowerofstemcellstreatingbleomycininducedlungfibrosis
AT chaturvedipankaj regenerativepowerofstemcellstreatingbleomycininducedlungfibrosis